| 1 |
NCT02893293 |
Recruiting |
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI |
|
- Drug: Ferumoxytol-enhanced magnetic resonance imaging
- Device: Magentic Resonance Imaging
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Evaluation of treatment response to decompression surgery and stem cell transplant
|
20 |
All |
8 Years to 40 Years (Child, Adult) |
NCT02893293 |
IRB-20253(osteonecrosis)
PEDSBONE0006 |
Osteonecrosis |
May 2015 |
November 2019 |
July 2020 |
September 8, 2016 |
December 11, 2018 |
|
- Lucile Packard Children's Hospital
Stanford, California, United States
|
|
| 2 |
NCT02598401 |
Recruiting |
The British Osteonecrosis Study |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of osteonecrosis
- Risk factors for development of osteonecrosis.
- Radiological features for prediction of progression of osteonecrosis
|
50 |
All |
10 Years to 25 Years (Child, Adult) |
NCT02598401 |
185365 |
BONES |
August 21, 2017 |
April 10, 2022 |
October 10, 2022 |
November 5, 2015 |
March 13, 2018 |
|
- Birmingham Children's Hospital
Birmingham, United Kingdom - Leeds Children's Hospital
Leeds, United Kingdom - St James's University Hospital
Leeds, United Kingdom - Southampton Children's Hospital
Southampton, United Kingdom
|
|
| 3 |
NCT02566681 |
Recruiting |
Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis |
|
- Biological: MSC construct for Osteonecrosis
|
Interventional
|
Phase 1 |
- Red de Terapia Celular
- Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- (and 3 more...)
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of serious adverse events related to the procedure.
- Rate of non-serious adverse events related to the procedure.
- Time to Repair the injury
- (and 3 more...)
|
10 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02566681 |
MSC/ONM
2012-005813-38 |
MSC/ONM |
September 2015 |
December 2018 |
December 2018 |
October 2, 2015 |
March 30, 2017 |
|
- Hospital Clínico Virgen de la Arrixaca
El Palmar, Murcia, Spain
|
|
| 4 |
NCT02932501 |
Recruiting |
Medication-related Osteonecrosis of the Jaw (MRONJ) Registry |
- Medication-related Osteonecrosis of the Jaw
- Bisphosphonate-Associated Osteonecrosis of the Jaw
|
- Procedure: Conservative treatment
- Procedure: Surgical treatment
- Procedure: Adjuvant non-surgical treatment
|
Observational
|
|
- AO Clinical Investigation and Documentation
- AOCMF
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Treatment outcome
- Pain
- Staging of osteonecrosis
- Site and size of the lesion
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02932501 |
RP_MRONJ_1.0 |
MRONJ |
August 14, 2017 |
June 2021 |
September 2021 |
October 13, 2016 |
December 6, 2017 |
|
- University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States - University of Texas Health Science Center
San Antonio, Texas, United States - Helsinki University Hospital
Helsinki, Finland - (and 13 more...)
|
|
| 5 |
NCT03405974 |
Recruiting |
Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip |
- Osteonecrosis of Femoral Head
- Osteonecrosis; Aseptic, Idiopathic
|
- Drug: Aspirin
- Drug: Placebo
|
Interventional
|
Phase 3 |
- McGill University Health Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Evaluation of radiologic progression of osteonecrosis
- Measure the percentage involvement of the femoral head on MRI.
|
114 |
All |
18 Years to 60 Years (Adult) |
NCT03405974 |
ONFH-ASA2016 |
|
October 12, 2017 |
November 1, 2020 |
November 1, 2021 |
January 23, 2018 |
January 24, 2018 |
|
- McGill University Health Centre
Montreal, Quebec, Canada
|
|
| 6 |
NCT01198080 |
Completed |
Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head |
|
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety of bone marrow derived CD133+ cells transplantation
- improve patient quality of life
- decrease hip articular change
- side effects
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01198080 |
Royan-Bone-003 |
|
August 2009 |
June 2013 |
June 2013 |
September 9, 2010 |
August 28, 2013 |
|
- Royan Institute
Tehran, Iran, Islamic Republic of
|
|
| 7 |
NCT02458937 |
Completed |
Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis |
|
- Other: Functional Mobility Assessment
- Other: GAITRite® System
- Other: Range of Motion
|
Observational
|
|
- St. Jude Children's Research Hospital
- Tennessee Physical Therapy Association
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Degree of Pain
- Functional Mobility
- Physiological Cost Index (PCI)
- (and 3 more...)
|
17 |
All |
8 Years to 29 Years (Child, Adult) |
NCT02458937 |
ONFUNC |
|
June 5, 2015 |
September 26, 2018 |
September 26, 2018 |
June 1, 2015 |
November 12, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
|
| 8 |
NCT03269214 |
Completed |
Use of Topical Phenytoin in Bisphosphonate-related Osteonecrosis of the Mandible |
- Osteonecrosis Due to Drugs, Jaw
|
- Drug: Topical Phenytoin 5%
|
Interventional
|
Not Applicable |
- Shiraz University of Medical Sciences
- Shahid Beheshti University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Soft tissue healing
- Pain
- Infection
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03269214 |
1396D22 |
|
September 1, 2012 |
October 31, 2016 |
March 30, 2017 |
August 31, 2017 |
September 1, 2017 |
|
|
|
| 9 |
NCT03180463 |
Not yet recruiting |
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells |
- Osteonecrosis of Femoral Head
|
- Drug: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
- Procedure: core decompression
|
Interventional
|
Phase 1
Phase 2 |
- Sclnow Biotechnology Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MRI imageological examination
- Harris Hip Score
|
30 |
All |
Child, Adult, Older Adult |
NCT03180463 |
SCLnow-IMIMH-05 |
|
July 2017 |
February 2018 |
August 2018 |
June 8, 2017 |
June 9, 2017 |
|
- Inner Mongolia International Mongolian Hospital
Hohhot, Inner Mongolia, China
|
|
| 10 |
NCT00505219 |
Completed |
Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head |
|
- Biological: Ixmyelocel-T
- Other: Standard of Care Only
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The progression of patients with UPenn Stage IIB or IIC disease to a more severe stage based on all available x-ray and MRI imaging. Patients who have a definitive procedure but do not have a valid assessment will be considered to have progressed.
- Time to progression (in months)
- Osteonecrosis volume measured by MRI
- Pain and quality of life questionnaires
|
11 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00505219 |
ABI 55-0705-1 |
ON-CORE |
September 2007 |
September 2010 |
December 2010 |
July 23, 2007 |
November 15, 2018 |
|
- Sinai Hospital of Baltimore
Baltimore, Maryland, United States - University of Minnesota Department of Orthopaedic Surgery
Minneapolis, Minnesota, United States - Lutheran Medical Center
Brooklyn, New York, United States
|
|
| 11 |
NCT01104324 |
Unknown † |
Osteonecrosis in Children With Acute Lymphoblastic Leukemia |
- Osteonecrosis
- Acute Lymphoblastic Leukemia
|
|
Observational
|
|
- Halton, Jacqueline, M.D.
- C17 Council
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- osteonecrosis 1 year post leukemia therapy
- Bone mass density and Osteonecrosis
- Is Bone loss/failure to accure bone mineral and ON
- (and 6 more...)
|
130 |
All |
5 Years to 18 Years (Child, Adult) |
NCT01104324 |
08/20E |
|
July 2009 |
December 2012 |
December 2012 |
April 15, 2010 |
April 15, 2010 |
|
- Alberta Children's Hospital
Calgary, Alberta, Canada - Stollery Children's Hospital
Edmonton, Alberta, Canada - BC Children's Hospital
Vancouver, British Columbia, Canada - (and 7 more...)
|
|
| 12 |
NCT02733900 |
Active, not recruiting |
Modifications of the Subchondral Bone in Aseptic Osteonecrosis of the Femoral Head |
|
- Procedure: femoral head removal
|
Interventional
|
Not Applicable |
- Lille Catholic University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Osseous modifications responsible of osteonecrosis
- Total cross-sectional area
- cortical bone area
- (and 14 more...)
|
34 |
Male |
25 Years to 70 Years (Adult, Older Adult) |
NCT02733900 |
RC-P0044 |
ONTF |
February 2016 |
April 2018 |
January 2019 |
April 12, 2016 |
November 22, 2018 |
|
- Hospital Group of the Catholic Institute of Lille
Lomme, France
|
|
| 13 |
NCT02198001 |
Unknown † |
Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction |
- Bisphosphonate-Associated Osteonecrosis of the Jaw
|
- Drug: tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
- Procedure: atraumatic extraction
|
Interventional
|
Not Applicable |
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of jaw osteonecrosis after tooth extraction
|
100 |
All |
50 Years and older (Adult, Older Adult) |
NCT02198001 |
B403201318408 |
PRF |
January 2014 |
January 2016 |
January 2017 |
July 23, 2014 |
July 23, 2014 |
|
- Cliniques Universitaires Saint Luc
Bruxelles, Belgium - Centre Hospitaliser Ambroise Paré
Mons, Belgium - Clinique et maternité Sainte Elisabeth
Namur, Belgium
|
|
| 14 |
NCT03269409 |
Recruiting |
Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis |
|
- Other: Saline
- Device: The Celution System (Cytori Therapeutics)
- Biological: Adipose Derived Regenerative Cells (ADRC)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety, as measured by the type of serious adverse events related to Hip Decompression supplemented with autologous ADRC transplantation compared to Hip Decompression alone.
- Safety, as measured by the number of serious adverse events related to Hip Decompression supplemented with autologous ADRC transplantation compared to Hip Decompression alone.
- Efficacy, as measured by change in MRI lesion volume.
- (and 6 more...)
|
25 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03269409 |
16-003846 |
|
November 15, 2017 |
November 2018 |
December 2018 |
August 31, 2017 |
November 2, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
|
| 15 |
NCT00781261 |
Unknown † |
Osteonecrosis of the Hip and Bisphosphonate Treatment |
|
- Drug: Zoledronic Acid
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of Sydney
- Novartis
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- reducing pain and disability in the hip
- reducing progression to femoral head collapse and the need for surgical intervention
|
120 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT00781261 |
570989 |
BONES |
August 2009 |
December 2013 |
December 2013 |
October 28, 2008 |
January 14, 2013 |
|
- Royal North Shore Hospital, Department of Rheumatology
Sydney, New South Wales, Australia - Princess Alexandra Hospital
Brisbane, Queensland, Australia - Royal Brisbane and Womens Hospital
Herston, Queensland, Australia - (and 2 more...)
|
|
| 16 |
NCT01666106 |
Active, not recruiting |
Osteonecrosis of the Jaw (ONJ) Case Registry |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Resolution rate and time to ONJ resolution
- The clinical features of ONJ, including severity and staging at enrollment
- The frequency of risk factors for incident ONJ
- (and 2 more...)
|
327 |
All |
18 Years and older (Adult, Older Adult) |
NCT01666106 |
20101102 |
|
October 1, 2012 |
April 9, 2021 |
April 9, 2021 |
August 16, 2012 |
October 18, 2018 |
|
- Research Site
Beverly Hills, California, United States - Research Site
Duarte, California, United States - Research Site
Denver, Colorado, United States - (and 61 more...)
|
|
| 17 |
NCT00477217 |
Withdrawn |
Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes from baseline after 3 months in a) knee pain scores (using the KOOS pain subscale), and b) volume of osteonecrotic lesion (indicated by bone marrow oedema) on MRI.
- Changes from baseline after 6 months in a) knee pain scores (using the KOOS pain subscale), and b) volume of osteonecrotic lesion (indicated by bone marrow oedema) on MRI.
- Safety as assessed by adverse events.
|
0 |
All |
40 Years to 85 Years (Adult, Older Adult) |
NCT00477217 |
CZOL446HAU21 |
|
January 2008 |
May 2009 |
May 2009 |
May 23, 2007 |
September 23, 2016 |
|
- Novartis Investigative Site
Gordon, Australia
|
|
| 18 |
NCT01133938 |
Completed |
Predictive Factors for the Development of Osteonecrosis After the Treatment of the Developmental Dislocated Hip |
- Predictors of Osteonecrosis of the Femoral Head After Treatment of the Dislocated Hip
|
|
Observational
|
|
- Orthopedic Hospital Vienna Speising
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Osteonecrosis of the femoral head
- Secondary reconstructive procedures due to residual acetabular dysplasia
|
79 |
All |
1 Month to 15 Years (Child) |
NCT01133938 |
OR-27052010 |
|
January 2009 |
February 2010 |
May 2010 |
May 31, 2010 |
June 3, 2010 |
|
- Orthopedic Hospital Vienna Speising
Vienna, Austria
|
|
| 19 |
NCT01700920 |
Completed |
PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells |
- Osteonecrosis of the Femoral Head
|
- Procedure: bone marrow aspirate
|
Interventional
|
Phase 2 |
- Red de Terapia Celular
- Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán
- Spanish National Health System
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
3 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01700920 |
CSM/ON/2011 |
CSM/ON/2011 |
July 2012 |
December 2015 |
December 2015 |
October 4, 2012 |
March 30, 2017 |
|
- University Hospital of Salamanca
Salamanca, Castilla y León, Spain
|
|
| 20 |
NCT03390777 |
Not yet recruiting |
Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw |
- Osteonecrosis Due to Drugs, Jaw
|
- Procedure: surgery
- Device: PRGF after surgery
|
Interventional
|
Phase 2
Phase 3 |
- University of Roma La Sapienza
- NYU College of Dentistry
- Universidade da Coruña
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- recurrence of disease
- morbidity
- post- and peri-operative pain
- quality of life (QoL)
|
150 |
All |
Child, Adult, Older Adult |
NCT03390777 |
26122017 |
|
September 2018 |
September 2021 |
January 2022 |
January 4, 2018 |
January 8, 2018 |
|
|
|
| 21 |
NCT01967160 |
Active, not recruiting |
Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid |
- Osteonecrosis of the Jaw
- Infection Leading to Hospitalization
|
|
Observational
|
|
- Amgen
- Aarhus University Hospital
|
Industry / Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 1. Incidence proportions of medically confirmed osteonecrosis of the jaw (ONJ) in XGEVA and zoledronic acid inception cohorts
- 2. Incidence proportions of infections leading to hospitalization in XGEVA and zoledronic acid inception cohorts
- 1. Incidence proportions of medically confirmed ONJ in the cohort switching from an oral or IV bisphosphonate (at the dose indicated for cancer patients to prevent skeletal related events) to XGEVA
- (and 4 more...)
|
2560 |
|
Child, Adult, Older Adult |
NCT01967160 |
20101363 |
|
October 1, 2011 |
September 30, 2019 |
September 30, 2019 |
October 22, 2013 |
December 11, 2018 |
|
|
|
| 22 |
NCT01529008 |
Recruiting |
Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head |
- Osteonecrosis of the Femoral Head
|
- Drug: Core decompression/PREOB® implantation
- Drug: Core decompression/placebo implantation
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of treatment responders
- Percentage of clinical responders
- percentage of radiological responders
- (and 7 more...)
|
118 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01529008 |
PREOB-ON3 |
|
November 2011 |
December 2018 |
January 2019 |
February 8, 2012 |
October 25, 2018 |
|
- Investigative site BE06
Aalst, Belgium - Investigative site BE01
Anderlecht, Belgium - Investigative site BE09
Antwerpen, Belgium - (and 34 more...)
|
|
| 23 |
NCT00289575 |
Unknown † |
MBCP Safety and Performance in the Osteonecrosis of Femur Head |
|
|
Interventional
|
Phase 2 |
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Infection and inflammation of the drilled area (blood and clinical assessment).
- Adverse events.
- Pain (Analogic Visual Scale)
- (and 2 more...)
|
12 |
All |
18 Years to 50 Years (Adult) |
NCT00289575 |
63 |
|
February 2006 |
|
February 2008 |
February 10, 2006 |
March 2, 2007 |
|
- Service de chirurgie orthopédique et traumatologique- Hôpital Pellegrin
Bordeaux, France
|
|
| 24 |
NCT01950858 |
Unknown † |
Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee |
- Spontaneous Osteonecrosis of the Knee
|
- Biological: Weight reduction
|
Interventional
|
Phase 1 |
- Assaf-Harofeh Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy
- Safety
- Reduction In AVN size by MRI
|
40 |
All |
40 Months to 85 Years (Child, Adult, Older Adult) |
NCT01950858 |
91/12*1 |
|
May 2012 |
May 2015 |
August 2015 |
September 26, 2013 |
September 26, 2013 |
|
- Assaf-Harofeh Medical Center
Zerifin, Israel
|
|
| 25 |
NCT01544712 |
Completed |
Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow |
- Non Traumatic Osteonecrosis of the Femoral Head (Hip)
|
- Procedure: core decompression with autologous bone marrow implantation
- Procedure: core decompression of the femoral head
|
Interventional
|
Not Applicable |
- University Hospital of Liege
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- reduction of total prosthesis
- Pain reduction
- functional status
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT01544712 |
Ref 2004/08 st 3 |
|
August 2004 |
September 2010 |
September 2010 |
March 6, 2012 |
March 6, 2012 |
|
- University of Liège
Liège, Belgium
|
|
| 26 |
NCT02448121 |
Active, not recruiting |
Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease |
- Avascular Necrosis of Bone
- Sickle Cell Disease
|
- Procedure: Autologous bone marrow stem cell graft
|
Interventional
|
Phase 1
Phase 2 |
- Federal University of Bahia
- Hospital Universitário Professor Edgard Santos
- Oswaldo Cruz Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Functional / Clinical Score of 10 points or more
- Numeric pain intensity scale (0-10)
- Disease progression defined as progression to a fractural stage of osteonecrosis
- (and 2 more...)
|
100 |
All |
18 Years to 55 Years (Adult) |
NCT02448121 |
CAAE 25000039812/2005-99
11738 |
|
August 2006 |
July 2018 |
August 2018 |
May 19, 2015 |
November 20, 2017 |
|
|
|
| 27 |
NCT01130389 |
Completed |
CONDOR Study of Osteonecrosis of the Jaws (TMJ) |
|
|
Observational
|
|
- Dental Practice-Based Research Network
- HealthPartners Institute
- Kaiser Permanente
- (and 2 more...)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
|
309 |
All |
40 Years and older (Adult, Older Adult) |
NCT01130389 |
106037
U01DE016747 |
|
January 2007 |
September 2008 |
September 2008 |
May 26, 2010 |
June 16, 2011 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Health Partners Dental Group
Minneapolis, Minnesota, United States - Health Partners Research Foundation
Minneapolis, Minnesota, United States - (and 2 more...)
|
|
| 28 |
NCT00601068 |
Completed |
Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis |
|
|
Observational
|
|
- University of Florida
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- establish complete database and publish descriptive paper
|
35 |
All |
30 Years to 90 Years (Adult, Older Adult) |
NCT00601068 |
32936
00065255 UFID |
|
December 2007 |
July 2011 |
July 2011 |
January 25, 2008 |
January 4, 2013 |
|
- University of Florida
Gainesville, Florida, United States
|
|
| 29 |
NCT00679978 |
Completed |
Vertebral Fracture and Osteonecrosis Associated With High-dose Glucocorticoid |
- Vertebral Fracture
- Osteonecrosis
- Rheumatic Diseases
|
|
Observational
|
|
- Saitama Medical University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- new vertebral fracture
- osteonecrosis of the femoral head
|
60 |
All |
20 Years and older (Adult, Older Adult) |
NCT00679978 |
SaitamaVFOFH
14211301 |
|
January 2001 |
October 2007 |
October 2007 |
May 19, 2008 |
September 18, 2009 |
|
|
|
| 30 |
NCT02941666 |
Recruiting |
Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- The quantity of mesenchymal stem cells present in the synovial fluid of patients with precollapse ON of the femoral head and postcollapse ON of the femoral head compared to patients without intraarticular hip pathology.
|
60 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT02941666 |
16-002241 |
|
September 2016 |
November 2021 |
November 2021 |
October 21, 2016 |
February 23, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 31 |
NCT01605383 |
Active, not recruiting |
Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head |
- Avascular Necrosis of Femur Head
|
- Biological: XCEL-MT-OSTEO-ALPHA
- Procedure: Standard treatment
|
Interventional
|
Phase 1
Phase 2 |
- Banc de Sang i Teixits
- Ministerio de Sanidad, Servicios Sociales e Igualdad
- Ministerio de Ciencia e Innovación, Spain
- European Regional Development Fund
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head
- Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head
- Bone regeneration by measuring the necrotic angle using the modified Kerboul method
- (and 4 more...)
|
24 |
All |
18 Years to 50 Years (Adult) |
NCT01605383 |
XCEL-MT-10-01
2010-023998-18 |
|
July 2012 |
April 11, 2018 |
December 2018 |
May 24, 2012 |
July 3, 2018 |
|
- Hospital Universitari Vall d'Hebron
Barcelona, Spain
|
|
| 32 |
NCT02735538 |
Completed |
Transcription Factor Runx2 in Necrotic Femoral Head Tissue |
- Osteonecrosis of Femoral Head
|
- Procedure: osteonecrosis of femoral head group
- Procedure: osteoarthritis group
|
Observational
|
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Runx2 mRNA expression in femoral head and neck tissue
- bone morphogenetic protein-2(BMP-2)
- bone morphogenetic protein-7(BMP-7)
- (and 2 more...)
|
30 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT02735538 |
ShengjingH_LQYang |
|
July 2009 |
June 2010 |
December 2011 |
April 12, 2016 |
April 13, 2016 |
|
|
|
| 33 |
NCT00265252 |
Unknown † |
Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis |
- Non-Traumatic Osteonecrosis
|
|
Interventional
|
Phase 4 |
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Merck Sharp & Dohme Corp.
- National Cheng-Kung University Hospital
- National Taiwan University Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- the cumulative of total hip replacement
- necrotic area
- Harris hip score
|
60 |
All |
20 Years to 85 Years (Adult, Older Adult) |
NCT00265252 |
fosamax 01 |
|
June 2005 |
|
June 2008 |
December 14, 2005 |
February 27, 2008 |
|
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan
|
|
| 34 |
NCT01892514 |
Active, not recruiting |
Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head |
|
- Procedure: core decompression
|
Interventional
|
Phase 3 |
- Istituto Ortopedico Rizzoli
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction of the total necrotic area by Magnetic Resonance Imaging (MRI)
- Pain reduction by measurement of the Visual Analog Scale (VAS)
- Functional status evaluated by Harris Hip Score (HHS) and Western Ontario McMaster Universities Arthritis Index (WOMAC)
- maintenance of structural integrity of the joint by Radiography (RX)
|
104 |
All |
18 Years to 60 Years (Adult) |
NCT01892514 |
AVN-13 |
AVN-13 |
April 2013 |
April 2018 |
April 2018 |
July 4, 2013 |
October 30, 2017 |
|
- 3rd Orthopaedic and Traumatologic Clinic, prevalently oncologic, Rizzoli Orthopaedic Institute
Bologna, Italy - S.S.D. Conservative Orthopaedic Surgery and Innovative Techniques, Rizzoli Orthopaedic Institute
Bologna, Italy - Orthopaedic and Traumatologic Department Policlinico di Modena
Modena, Italy
|
|
| 35 |
NCT02721940 |
Unknown † |
Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis |
|
- Procedure: Control group
- Biological: Mononuclear Cells
- Biological: Platelets
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Chinese PLA General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Change of Magnetic resonance imaging(MRI)
- Change of Three-dimensional CT
- Change of X-ray film
- (and 4 more...)
|
100 |
All |
14 Years to 55 Years (Child, Adult) |
NCT02721940 |
PLAGH_001 |
|
February 2012 |
January 2015 |
May 2016 |
March 29, 2016 |
March 29, 2016 |
|
|
|
| 36 |
NCT03040778 |
Recruiting |
Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) |
- Medication-related Osteonecrosis of the Jaw
- Bisphosphonate-related Osteonecrosis of the Jaw
- Avascular Necrosis
|
- Drug: Pentoxifylline
- Drug: Placebo
- Drug: Tocopherol
|
Interventional
|
Phase 3 |
- University of Washington
- University of Alabama at Birmingham
- New York Center for Orthognathic and Maxillofacial Surgery
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Bone exposure area (mm^2)
- Change in MRONJ Stage
- Change in Pain
- (and 3 more...)
|
100 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT03040778 |
STUDY00004779 |
|
April 1, 2018 |
January 2020 |
January 2020 |
February 2, 2017 |
May 14, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Michigan
Ann Arbor, Michigan, United States - New York Center for Orthognathic and Maxillofacial Surgery
Lake Success, New York, United States - University of Washington
Seattle, Washington, United States
|
|
| 37 |
NCT00821470 |
Completed |
Treatment of Osteonecrosis of the Femoral Head by Bone Marrow Transplantation |
|
- Procedure: core decompression
- Procedure: Bone marrow implantation into the necrotic lesion
|
Interventional
|
Phase 1 |
- Erasme University Hospital
- Fonds National de la Recherche Scientifique
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- WOMAC Score
- Disease progression defined as progression to a fractural stage of osteonecrosis
|
21 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00821470 |
ref. 98/20 |
|
January 1999 |
September 2008 |
September 2008 |
January 13, 2009 |
January 14, 2009 |
|
- Erasme Hospital
Brussels, Belgium
|
|
| 38 |
NCT00532220 |
Completed |
Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial |
- Osteonecrosis of the Knee
- Bone Marrow Edema of the Knee
|
- Drug: Ibandronate IV
- Drug: Placebo
|
Interventional
|
Phase 3 |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- clinical outcome (pain [VAS score])
- radiological outcome (MRI knee)
- number of salvage therapies needed in case persistence is observed during placebo therapy
|
30 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT00532220 |
Ro 200-5450 |
|
December 2007 |
August 2015 |
August 2015 |
September 20, 2007 |
August 26, 2015 |
|
- University Hospital
Basel, Switzerland
|
|
| 39 |
NCT01619124 |
Recruiting |
Osteonecroses in Pediatric Patients With ALL |
- Osteonecrosis
- Acute Lymphoblastic Leukaemia
- Lymphoblastic Lymphoma
|
|
Observational
|
|
- Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu
- Heinrich-Heine University, Duesseldorf
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- occurence of early ON stages
- ON incidence
|
400 |
All |
10 Years to 18 Years (Child, Adult) |
NCT01619124 |
DKS 2011.11 |
OPAL |
March 2012 |
March 2016 |
March 2020 |
June 14, 2012 |
March 5, 2014 |
|
- Department of Paediatric and Adolescend Medicine, University Aachen
Aachen, Germany - Department of Pediatrics, Haematology and Oncology, University Bonn
Bonn, Germany - Department for Children and Adolescent Helth Chemnitz gGmbH
Chemnitz, Germany - (and 22 more...)
|
|
| 40 |
NCT01325142 |
Completed |
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer |
- Bone Diseases
- Metastases
- Osteonecrosis
- Bisphosphonate-Associated Osteonecrosis of the Jaw
|
|
Observational
|
|
- University of Michigan
- National Institute of Dental and Craniofacial Research (NIDCR)
- Indiana University
- (and 2 more...)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- To identify clinical and epidemiologic characteristics associated with ONJ in patients with metastatic bone disease treated with a nitrogen containing bisphosphonate.
- To identify single nucleotide polymorphisms (SNPs) in genes affected by osteoclast inhibiting therapy that are associated with an increased risk of developing ONJ in patients with metastatic bone disease treated with nitrogen containing bisphosphonates.
- To generate a multifactorial index of ONJ risk by multivariate analysis of the clinical, epidemiologic and genetic factors
|
271 |
All |
21 Years and older (Adult, Older Adult) |
NCT01325142 |
HUM00040101
5K23DE020197-02 |
|
August 2010 |
November 2014 |
November 2014 |
March 29, 2011 |
December 2, 2014 |
|
- University of Michigan
Ann Arbor, Michigan, United States
|
|
| 41 |
NCT00813267 |
Unknown † |
Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head |
- Osteochondritis of the Femoral Head
|
- Biological: mesenchymal stem cell infusion
- Biological: bone marrow mononuclear cell infusion
|
Interventional
|
Early Phase 1 |
- Jianming Tan
- Fuzhou General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The femoral head blood-supply artery angiographies and the areas of femoral head necrosis
- Coxa joint paining
- Walking distance
- (and 2 more...)
|
15 |
All |
12 Years to 60 Years (Child, Adult) |
NCT00813267 |
fuzhough1221 |
|
December 2009 |
August 2011 |
August 2015 |
December 23, 2008 |
October 10, 2012 |
|
- Fuzhou General Hospital
Fuzhou, Fujian, China
|
|
| 42 |
NCT01998607 |
Completed |
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw |
- Solid Tumours
- Bone Metastasis
|
|
Observational
|
|
|
Industry |
- Observational Model: Other
- Time Perspective: Cross-Sectional
|
- Proportion of participating oncology practitioners prescribing XGEVA® who are aware of the SPC statements pertaining to ONJ (each question pertaining to a SPC statement will be assessed seperately at the end of each survey round)
|
420 |
All |
Child, Adult, Older Adult |
NCT01998607 |
20110102 |
|
February 4, 2013 |
May 15, 2015 |
May 15, 2015 |
December 2, 2013 |
January 9, 2018 |
|
|
|
| 43 |
NCT02890537 |
Completed |
Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head |
- Avascular Necrosis of Femur Head
|
- Drug: Core decompression/PREOB® implantation
- Drug: Core decompression/BMC implantation
|
Interventional
|
Phase 2 |
- Erasme University Hospital
- University Hospital of Liege
- Bone Therapeutics S.A
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of responder subjects
- Potential occurrence of any AE or SAE, related to the product or to the procedure, using patient open non-directive questionnaire, physical examination and laboratory measurements
- Percentage of subjects progressing to fractural stage (ARCO stage III or higher), as assessed by conventional X-ray
- (and 5 more...)
|
82 |
All |
18 Years and older (Adult, Older Adult) |
NCT02890537 |
2003/281 |
PREOB-ON2 |
October 2003 |
May 2011 |
January 2015 |
September 7, 2016 |
September 7, 2016 |
|
- Investigative site 01
Brussels, Belgium - Investigative site 02
Liege, Belgium
|
|
| 44 |
NCT00874211 |
Active, not recruiting |
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases |
- Breast Cancer
- Lung Cancer
- Metastatic Cancer
- (and 4 more...)
|
- Procedure: assessment of therapy complications
|
Observational
|
|
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Novartis
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Diagnosis of confirmed osteonecrosis of the jaw (ONJ)
- Disease-specific estimates of the confirmed cumulative incidence at 3 years of ONJ
- Clinical presentation and natural history of ONJ
- (and 3 more...)
|
3500 |
All |
up to 120 Years (Child, Adult, Older Adult) |
NCT00874211 |
S0702
U10CA037429 |
|
December 2008 |
September 2018 |
January 2019 |
April 2, 2009 |
October 11, 2018 |
|
- Regional Medical Center
Anniston, Alabama, United States - Providence Cancer Center at Providence Hospital
Mobile, Alabama, United States - Providence Cancer Center
Anchorage, Alaska, United States - (and 450 more...)
|
|
| 45 |
NCT03418454 |
Recruiting |
The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw |
- Oral Squamous Cell Carcinoma
- Medication Related Osteonecrosis of the Jaw
- Oral Epithelial Dysplasia
|
- Diagnostic Test: Buccal mucosa samples for Extraction of BACTERIAL DNA
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Microbiome characterization day 1 of the study
- Microbiome characterization month 3 of the study
- Microbiome characterization month 6 of the study
- (and 2 more...)
|
150 |
All |
20 Years to 90 Years (Adult, Older Adult) |
NCT03418454 |
BRZ 0062-17 CTIL |
|
December 14, 2017 |
December 31, 2021 |
December 31, 2021 |
February 1, 2018 |
March 9, 2018 |
|
- Barzilai medical Center
Ashkelon, Israel
|
|
| 46 |
NCT02114489 |
Terminated |
Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis |
- Aseptic Hip Necrosis
- Hip Necrosis
|
- Drug: ibandronate
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Brigitte Jolles, MD
- University of Lausanne Hospitals
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- VAS pain
- Imagery assessment
- The Western Ontario and McMaster Universities Arthritis Index (Womac scale)
- (and 3 more...)
|
8 |
All |
18 Years to 50 Years (Adult) |
NCT02114489 |
SwissMedic 136/13 |
|
June 2014 |
March 2017 |
March 2017 |
April 15, 2014 |
May 17, 2017 |
|
- Lausanne University Hospital
Lausanne, Vaud, Switzerland
|
|
| 47 |
NCT01048710 |
Completed |
Treatment of Medial Compartmental Osteoarthritis Grade 1-4 With TomoFix™ Small or Conservatively |
- Osteoarthritis, Knee
- Osteonecrosis
|
|
Observational
|
|
- Synthes GmbH
- Johnson & Johnson K.K. Medical Company
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Knee Injury and Osteoarthritis Outcome Score (KOOS)
- Patient-evaluated function of the knee and quality of life, a. assessed with the Oxford-12-item knee score b. assessed with the WOMAC (as calculated from the KOOS)
- Clinician-evaluated function of the knee, assessed with the Japanese Orthopaedic Association (JOA) score
- (and 8 more...)
|
148 |
All |
40 Years and older (Adult, Older Adult) |
NCT01048710 |
Tomofix_small |
|
July 1, 2009 |
March 31, 2015 |
May 7, 2018 |
January 14, 2010 |
August 22, 2018 |
|
- Toyama Municipal Hospital
Toyama-city, Japan
|
|
| 48 |
NCT02069340 |
Withdrawn |
Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid |
- Malignant Neoplasm
- Musculoskeletal Complications
|
- Drug: zoledronic acid
- Other: pharmacological study
|
Interventional
|
Not Applicable |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Plasma concentrations of Zol collected at visits 2, 3, 4, and 5
- Urine concentrations of Zol collected at visits 2, 3, 4, and 5
- Jawbone tissue concentrations of Zol collected during surgical treatment for BRONJ
- Identify potential risk factors for BRONJ
|
0 |
All |
Child, Adult, Older Adult |
NCT02069340 |
0S-13-3
NCI-2014-00207
P30CA014089 |
|
June 2016 |
December 2020 |
June 2021 |
February 24, 2014 |
April 11, 2017 |
|
- USC Norris Comprehensive Cancer Center
Los Angeles, California, United States - J.Craig Venter Institute-San Diego
San Diego, California, United States
|
|
| 49 |
NCT01201330 |
Completed |
DPBRN Retrospective Cohort Study of Osteonecrosis of the Jaw |
|
|
Observational
|
|
- Dental Practice-Based Research Network
- HealthPartners Institute
- Kaiser Permanente
- (and 2 more...)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
572606 |
All |
41 Years and older (Adult, Older Adult) |
NCT01201330 |
106030
U01DE016747 |
|
January 2007 |
May 2008 |
May 2008 |
September 14, 2010 |
June 16, 2011 |
|
- Gregg H. Gilbert, DDS, MBA
Birmingham, Alabama, United States
|
|
| 50 |
NCT00592982 |
Completed |
Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging |
- Bisphosphonate-associated ONJ
- Osteomyelitis of the Jaw
- Osteolytic Lesions of the Jaw
- Osteoradionecrosis of the Jaw
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT00592982 |
73319 |
|
October 2006 |
August 2013 |
August 2013 |
January 14, 2008 |
October 25, 2013 |
|
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
|
|
| 51 |
NCT02632903 |
Withdrawn |
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study |
- Osteoporosis
- Osteonecrosis
- Acute Lymphoblastic Leukemia
|
|
Interventional
|
Phase 2 |
- Children's Hospital of Eastern Ontario
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the effect of zoledronic acid on preventing incident vertebral fractures
|
0 |
All |
8 Years to 16 Years (Child) |
NCT02632903 |
ZA8DEC2015 |
|
October 2016 |
March 2018 |
August 20, 2018 |
December 17, 2015 |
August 22, 2018 |
|
- Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
|
|
| 52 |
NCT00462098 |
Completed |
Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates |
|
- Device: hyperbaric oxygen
- Device: non-treated control group
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical outcome assessments. Effect of HBO as an adjunct to the routine treatment of ONJ will be evaluated by physical exam and pain scores
- Quality of life measurements by the Duke Health Profile
- Laboratory measures of bone turnover
- Molecular indicators of osteoclast activation (RANK, RANKL, OPG, pAKt)
|
54 |
All |
Child, Adult, Older Adult |
NCT00462098 |
Pro00007527 |
|
August 2006 |
December 2010 |
December 2010 |
April 18, 2007 |
February 21, 2013 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
|
| 53 |
NCT00858585 |
Active, not recruiting |
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study |
|
|
Observational
|
|
- University of Michigan Rogel Cancer Center
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Single nucleotide polymorphisms
|
124 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00858585 |
UMCC 2008.066
HUM 22831 |
|
March 2009 |
May 2011 |
August 2019 |
March 10, 2009 |
October 30, 2018 |
|
- University of Michigan
Ann Arbor, Michigan, United States
|
|
| 54 |
NCT02077647 |
Active, not recruiting |
Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee |
- Osteoarthritis, Knee
- Osteonecrosis
|
|
Observational
|
|
- AO Clinical Investigation and Documentation
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Function of the knee
- Patient-evaluated function of the knee and quality of life
- Clinician-evaluated function of the knee
- (and 10 more...)
|
20 |
All |
40 Years and older (Adult, Older Adult) |
NCT02077647 |
FR_Tomofix |
|
March 2014 |
April 2015 |
October 2019 |
March 4, 2014 |
January 24, 2017 |
|
- Nagasaki University
Nagasaki city, Japan - Osaka Koseinenkin Hospital
Osaka, Japan - Hashiba Orthopaedic Clinic
Toyama-city, Japan - Toyama Municipal Hospital
Toyama-city, Japan
|
|
| 55 |
NCT02218554 |
Unknown † |
Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay |
- Bisphosphonate-related Osteonecrosis of the Jaw
|
|
Interventional
|
Not Applicable |
- Micromedic Technologies Ltd
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- For each subject, the primary endpoint is the presence or absence of SNPs or other genetic alterations obtained from the assay for blood samples
- For each subject, the secondary endpoint is the presence or absence of additional/alternative SNPs or other genetic alterations using GWAS analysis and/or Full Exome Sequencing (FES) from the assay for blood samples
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT02218554 |
CL-BNJ-001-PR |
BRONJ |
January 2012 |
December 2014 |
December 2014 |
August 18, 2014 |
August 18, 2014 |
|
- Sheba Medical Center
Tel Hashomer, Israel - Sheba Medical Center
Tel Hashomer, Israel
|
|
| 56 |
NCT00260897 |
Unknown † |
Molecular Genetic Study of Avascular Necrosis of the Femoral Head |
|
|
Observational
|
|
- National Health Research Institutes, Taiwan
|
Other |
- Observational Model: Defined Population
- Primary Purpose: Screening
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
500 |
All |
Child, Adult, Older Adult |
NCT00260897 |
EC 9206002 |
|
May 2003 |
|
April 2008 |
December 2, 2005 |
May 8, 2007 |
|
- Division of Molecular and Genomic Medicine, National Health Research Institutes
Miaoli County, Taiwan
|
|
| 57 |
NCT01875458 |
Recruiting |
Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use |
- Osteoporosis, With or Without Treatment
- Bisphosphonate Treatment
- Atypical Femur Fracture
- (and 2 more...)
|
|
Observational
|
|
- University of Pennsylvania
|
Other |
- Observational Model: Ecologic or Community
- Time Perspective: Prospective
|
- Absorption, Distribution, Metabolism, Excretion (ADME) Profiling of DNA from all sample types vs. normative data for the ADME panel and across study groups
- Differential expression of miRNA biomarkers across participant groups within the study
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT01875458 |
815570 |
|
May 2013 |
April 2028 |
April 2028 |
June 11, 2013 |
September 11, 2018 |
|
- Online participation via https://www.surveymonkey.com/s/bisphos4ctg
Philadelphia, Pennsylvania, United States - University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
|
|
| 58 |
NCT02661139 |
Recruiting |
Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction |
- Head and Neck Cancer
- Osteonecrosis
- Osteoradionecrosis
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- implant survival rate
- bone resorption, as evaluated with cone-beam computed tomography
- prosthesis survival rate
- (and 3 more...)
|
55 |
All |
Child, Adult, Older Adult |
NCT02661139 |
B049201525496 |
O-BRIDGE |
June 2013 |
December 2020 |
December 2023 |
January 22, 2016 |
January 22, 2016 |
|
- General Hospital Saint-John Bruges
Bruges, Belgium
|
|
| 59 |
NCT00434447 |
Completed |
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases |
|
|
Interventional
|
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Safety assessed by incidence of renal impairment, osteonecrosis of the Jaw (ONJ), adverse events and serious adverse events. Efficacy assessed by incidence of skeletal related events (SREs).
|
73 |
All |
18 Years and older (Adult, Older Adult) |
NCT00434447 |
CZOL446EAU22 |
|
December 2006 |
September 2009 |
|
February 13, 2007 |
February 27, 2017 |
|
- Novartis Investigative Site
Canberra, Australian Capital Territory, Australia - Novartis Investigative Site
Concord, New South Wales, Australia - Novartis Investigative Site
Liverpool, New South Wales, Australia - (and 7 more...)
|
|
| 60 |
NCT02683252 |
Recruiting |
Musculoskeletal Non-tumoral Pathology Quantitative Perfusion |
- Osteonecrosis
- Pseudarthrosis
- Compartment Syndrome
|
- Other: T1 mapping and MR perfusion acquisition
|
Interventional
|
Not Applicable |
- Central Hospital, Nancy, France
- University Hospital, Lille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Variation of the plasmatic volume estimation in the 5 study groups (arms) and between the images acquired in the two inclusion sites.
- Variation of the plasma-extra-cellular space transfer constant in the 5 study groups (arms) and between the images acquired in the two inclusion sites.
- Variation of the extra-cellular space-plasma transfer constant (backflow constant) in the 5 study groups (arms) and between the images acquired in the two inclusion sites.
- Variation of the extra-cellular extra-vascular space volume in the 5 study groups (arms) and between the images acquired in the two inclusion sites.
|
400 |
All |
18 Years and older (Adult, Older Adult) |
NCT02683252 |
RCB: 2015-A01604-45 |
AFRONT |
February 12, 2016 |
February 12, 2019 |
February 12, 2020 |
February 17, 2016 |
August 23, 2018 |
|
- Service d'Imagerie Guilloz, CHRU-Nancy
Nancy, Lorraine, France - CCIAL, CHRU-Lille
Lille, Nord-pas-de-Calais, France
|
|
| 61 |
NCT02332681 |
Unknown † |
Osteoporosis and Knee Insufficiency Fracture |
- Osteoporosis
- Osteoporotic Fractures
- Osteonecrosis
|
|
Observational
|
|
- University of Sao Paulo General Hospital
- University of Campinas, Brazil
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- New fracture
- Bone Mineral Density
|
300 |
All |
45 Years and older (Adult, Older Adult) |
NCT02332681 |
38151514.8.0000.5404 |
|
December 2014 |
December 2017 |
December 2017 |
January 7, 2015 |
January 7, 2015 |
|
- University of Campinas
Campinas, São Paulo, Brazil
|
|
| 62 |
NCT01806766 |
Completed |
Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings |
- Osteonecrosis
- Osteoarthritis
|
- Procedure: Ceramic on Ceramic bearing
- Procedure: Ceramic on Highly crosslinked polyethylene bearing
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Harris hip score
- Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT01806766 |
XPECCC |
|
January 1998 |
January 2000 |
December 2012 |
March 7, 2013 |
March 7, 2013 |
|
- Ewha Womans University Mokdong Hospital
Seoul, Korea, Republic of
|
|
| 63 |
NCT01345097 |
Completed |
A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients |
- Osteonecrosis
- Osteoarthritis
|
- Device: Total Hip Arthroplasty
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Harris hip score
- Improvement in the Range of Motion
|
200 |
All |
20 Years to 95 Years (Adult, Older Adult) |
NCT01345097 |
THRProxima |
|
May 2004 |
March 2006 |
March 2011 |
April 29, 2011 |
April 29, 2011 |
|
- Ewha Womans University Mokdong Hosptial
Seoul, Korea, Republic of
|
|
| 64 |
NCT01622465 |
Completed |
Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty |
- Osteoarthritis, Hip
- Osteonecrosis
|
- Behavioral: Ergometer cycling
- Behavioral: Conventional exercises
|
Interventional
|
Phase 2 |
- University of Campinas, Brazil
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in hip function at three months
- Change from baseline in physical performance of lower limbs at three months.
- Change from baseline in health-related quality of life (HRQOL)at three months by generic questionnaire
- Change from baseline in health-related quality of life (HRQOL) at three months by specific questionnaire
|
14 |
All |
60 Years and older (Adult, Older Adult) |
NCT01622465 |
403/2011 |
|
August 2011 |
December 2013 |
April 2014 |
June 19, 2012 |
December 4, 2014 |
|
- Hospital das Clínicas da Universidade Estadual de Campinas
Campinas, São Paulo, Brazil
|
|
| 65 |
NCT02291900 |
Unknown † |
Talar Avascular Necrosis: Surgical Angiogenesis vs. Core Decompression |
- Avascular Necrosis of Bone
|
- Procedure: core decompression
|
Interventional
|
Not Applicable |
- BG Trauma Center Ludwigshafen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Pain reduction
- Lower Extremity Functional Scale
- Revascularization (Association International de Recherche sur la Circulation Osseuse-Criteria)
- American Orthopaedic Foot and Ankle Society- Ankle and Hindfoot Score
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02291900 |
BGU - 01/14 |
TalarAVN |
February 2014 |
November 2015 |
November 2016 |
November 17, 2014 |
November 18, 2014 |
|
- BG Trauma Center Ludwigshafen
Ludwigshafen, Rheinland-Pfalz, Germany
|
|
| 66 |
NCT02289976 |
Unknown † |
Talar Avascular Necrosis: Surgical Angiogenesis vs. Core Decompression |
- Avascular Necrosis of Bone
|
- Procedure: core decompression
|
Interventional
|
Not Applicable |
- BG Trauma Center Ludwigshafen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Pain reduction
- Revascularization of the talus in the MRI
- Lower Extremity Functional Scale
- American Orthopaedic Foot and Ankle Society (AOFAS-) Ankle-Hindfoot-Score
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02289976 |
BGU-01/14 |
TalarAVN |
February 2014 |
November 2014 |
November 2016 |
November 13, 2014 |
November 13, 2014 |
|
- BG Trauma Center Ludwigshafen
Ludwigshafen, Rheinland-Pfalz, Germany
|
|
| 67 |
NCT03620149 |
Not yet recruiting |
Reduced Dose-density of Denosumab for Unresectable GCTB |
|
- Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
|
Interventional
|
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
- Amgen
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Osteonecrosis of the jaw (ONJ) incidence
- Overall survival
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT03620149 |
EORTC 1762-STBSG
2018-002096-17
20177203 |
REDUCE |
January 2019 |
January 2024 |
January 2025 |
August 8, 2018 |
November 7, 2018 |
|
|
|
| 68 |
NCT00913679 |
Unknown † |
A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty |
- Osteonecrosis
- Femoral Neck Fracture
- Implant Failure
|
- Procedure: Surgical approach (ReCap Hip Resurfacing System)
|
Interventional
|
Not Applicable |
- University of Aarhus
- Aarhus University Hospital
- Zimmer Biomet
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- femoral head blood flow, evaluated by Laser Doppler Flowmetry
- femoral head metabolism, evaluated by microdialysis
- implant fixation, evaluated by RSA (radiostereogrammetric analysis)
- (and 3 more...)
|
50 |
All |
30 Years to 60 Years (Adult) |
NCT00913679 |
20070082 |
|
November 2008 |
November 2013 |
November 2013 |
June 4, 2009 |
November 4, 2011 |
|
- Aarhus University Hospital, Department of Orthopaedic Surgery, Tage-Hansens Gade 2
Aarhus C, Aarhus County, Denmark
|
|
| 69 |
NCT00412841 |
Terminated
Has Results |
Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus |
|
- Drug: Atorvastatin
- Procedure: MRI, Venipuncture
- Drug: Placebo
|
Interventional
|
Phase 2 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Number of Participants With AVN After 9 Months
- Number of Participants With AVN After 4 Months
- To Determine if Atorvastatin is Effective in Lowering Serum Lipid Levels Chol, TG, HDL, & LDL in SLE Patients
- To Determine if Atorvastatin Has an Anti-inflammatory Effect in Active SLE That Reduces Biological Markers of the Inflammatory Process (ESR, Hs-CRP) and Reduces Disease Activity Assessed by Serology (C3, C4, Anti-dsDNA) or Clinical Instrument (SLEDAI)
|
43 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT00412841 |
H-8795 |
|
November 2002 |
January 2008 |
January 2008 |
December 19, 2006 |
November 22, 2018 |
March 3, 2016 |
- The New York University Hospital For Joint Diseases
New York, New York, United States
|
|
| 70 |
NCT00808613 |
Withdrawn |
Optetrak Posterior Stabilized Versus Optetrak Hi-Flex |
- Total Knee Replacement Due to Osteoarthritis, Osteonecrosis, Rheumatoid
- Arthritis and/or Post-traumatic Degenerative Problems
|
- Device: Optetrak PS
- Device: Optetrak Hi-Flex
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary outcome of interest is knee range of motion (ROM), specifically the degree of flexion.
- Knee Society Score (KSS)
- Hospital for Special Surgery (HSS) Knee Score
- (and 4 more...)
|
0 |
All |
50 Years to 80 Years (Adult, Older Adult) |
NCT00808613 |
CR07-001 |
|
December 2008 |
January 2012 |
January 2012 |
December 16, 2008 |
February 26, 2013 |
|
- Hampton Roads Orthopedics
Newport News, Virginia, United States
|
|
| 71 |
NCT01763684 |
Terminated |
Oxford Signature vs. Conventional Global Study |
- Osteoarthritis
- Osteoarthritis, Knee
- Osteonecrosis
|
- Device: Signature Custom Guides
- Procedure: Conventional Instrumentation
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Knees Achieving Optimal Alignment
- Average Number of Instrument Cases Used
- Operative Time
- (and 9 more...)
|
266 |
All |
21 Years and older (Adult, Older Adult) |
NCT01763684 |
ORTHO.CR.GK7 |
|
September 2012 |
August 2016 |
August 2016 |
January 9, 2013 |
September 10, 2018 |
|
- Orthopedic and Sports Medicine Center
Elkhart, Indiana, United States - The Orthopaedic Center
Rockville, Maryland, United States - University of Missouri-Columbia Hospital and Clinics
Columbia, Missouri, United States - (and 4 more...)
|
|
| 72 |
NCT03197623 |
Recruiting |
Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids |
- Osteopenia
- Osteoporosis
- Osteonecrosis
|
- Drug: LLP2A-ALENDRONATE
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Nancy E. Lane, MD
- California Institute for Regenerative Medicine (CIRM)
- University of California, Davis
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Dose limiting Adverse events
- Severe infusion reactions
- Grade 2 elevated creatinine
|
50 |
All |
20 Years to 75 Years (Adult, Older Adult) |
NCT03197623 |
20161825
LLP2A-001 |
|
October 14, 2016 |
January 2020 |
June 2020 |
June 23, 2017 |
June 28, 2018 |
|
- West Coast Clinical Trials (WCCT)
Cypress, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States - Metroplex Clinical Research Center
Dallas, Texas, United States
|
|
| 73 |
NCT02338596 |
Completed |
Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old |
- Hip Replacement, Total
- Osteonecrosis of Femoral Head
- Coxarthrosis
|
- Procedure: Total hip replacement
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Thigh pain
- Harris hip score
|
111 |
All |
19 Years to 50 Years (Adult) |
NCT02338596 |
Shortstem005 |
|
June 2001 |
January 2014 |
March 2014 |
January 14, 2015 |
January 14, 2015 |
|
|
|
| 74 |
NCT00939900 |
Completed
Has Results |
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head |
- Avascular Necrosis of Femoral Head
|
- Drug: zoledronic acid (aclasta)
|
Interventional
|
Phase 3 |
- Seoul National University Bundang Hospital
- Novartis Korea Ltd.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Femoral Head Collapse Within 24 Months
- Collpase Rate of Femoral Head
- Change of HHS (Harris Hip Scores), WOMAC Score, SF-36
- (and 2 more...)
|
110 |
All |
19 Years to 65 Years (Adult, Older Adult) |
NCT00939900 |
CZOL446HKR08T |
EZAPCOFH |
July 2009 |
June 2012 |
June 2012 |
July 15, 2009 |
July 2, 2015 |
July 2, 2015 |
- Seoul national University Bundang Hospital
Seongnam-Si, Gyeonggi-do, Korea, Republic of
|
|
| 75 |
NCT02367417 |
Recruiting |
Prospective Clinical 5-year Follow-up of the LINK® Endo-Model® SL® |
- Bone Necrosis
- Arthritis/Arthrosis
- Failure of Prosthetic Joint Implant
|
|
Observational
|
|
- Waldemar Link GmbH & Co. KG
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- KOOS
- Complications
- Rate of subsequent surgical interventions
- (and 2 more...)
|
150 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02367417 |
RP02 |
|
August 14, 2017 |
November 2024 |
May 2025 |
February 20, 2015 |
February 14, 2018 |
|
- Medizinische Fakultät Orthopädische Universitätsklinik (KORT)
Magdeburg, Sachsen-Anhalt, Germany - Universitätsklinikum Carl Gustav Carus
Dresden, Sachsen, Germany - Evangelisches Waldkrankenhaus Spandau
Berlin, Germany
|
|
| 76 |
NCT00921557 |
Completed
Has Results |
Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents |
|
- Drug: Alendronate
- Drug: Placebo
- Dietary Supplement: Calcium carbonate/vitamin D
|
Interventional
|
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD
- Percentage of Participants Developing New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures
- Percent Change From Baseline to Weeks 24 and 48 in Whole Body (With Head) BMD
- (and 17 more...)
|
52 |
All |
11 Years to 24 Years (Child, Adult) |
NCT00921557 |
P1076
10669
IMPAACT P1076 |
|
November 2009 |
January 2016 |
January 2017 |
June 16, 2009 |
July 21, 2017 |
March 28, 2017 |
- David Geffen School of Medicine at UCLA NICHD CRS
Los Angeles, California, United States - Pediatric Perinatal HIV Clinical Trials Unit CRS
Miami, Florida, United States - USF - Tampa NICHD CRS
Tampa, Florida, United States - (and 7 more...)
|
|
| 77 |
NCT02139007 |
Completed
Has Results |
Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study |
|
|
Interventional
|
Phase 4 |
- University of Alabama at Birmingham
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- All Study Sites--Length of Contracting Procedures
- All Study Sites--Length of Time to Site IRB Approval
- All Study Sites-Length of Time to 1st Participant Enrolled
- (and 3 more...)
|
27 |
Female |
65 Years to 100 Years (Older Adult) |
NCT02139007 |
F120404006 |
EDGE |
June 2014 |
June 2016 |
July 2016 |
May 15, 2014 |
May 12, 2017 |
May 12, 2017 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 78 |
NCT01458782 |
Active, not recruiting |
ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee |
- Osteochondritis Dissecans
- Osteoarthritis
- Cartilage Injury
- Osteonecrosis
|
- Procedure: Treatment of cartilage defects in the knee
|
Interventional
|
Phase 2
Phase 3 |
- University Hospital of North Norway
- University of Tromso
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Perceived treatment efficacy as change from baseline in KOOS score
- Change from baseline in radiological signs of arthritis progression
- Perceived treatment efficacy as change from baseline in Lysholm score
- Time to failure
|
80 |
All |
18 Years to 60 Years (Adult) |
NCT01458782 |
2011/1159-3 |
|
October 2011 |
October 2014 |
October 2024 |
October 25, 2011 |
October 28, 2016 |
|
- University Hospital of North Norway
Tromso, Troms, Norway
|
|
| 79 |
NCT03488368 |
Enrolling by invitation |
Longterm Renal Oucomes of STOP-IgAN Trial Participants |
|
|
Observational
|
|
|
Other |
- Observational Model: Other
- Time Perspective: Retrospective
|
- Time to the first occurring event of the binary composite of all-cause death, end-stage renal disease (ESRD) and of estimated glomerular filtration rate (eGFR)-loss >40% based on available data by March 31, 2018.
- all-cause death
- end-stage renal disease (ESRD)
- (and 4 more...)
|
156 |
All |
Child, Adult, Older Adult |
NCT03488368 |
STOP IgAN - Longterm |
|
February 1, 2018 |
July 31, 2018 |
December 31, 2018 |
April 5, 2018 |
April 11, 2018 |
|
- Medical Clinic II, University Hospital Aachen
Aachen, Germany
|
|
| 80 |
NCT03541122 |
Active, not recruiting |
Three Novel Radiological Indicators for Diagnosis of Adult Acetabular Dysplasia |
|
- Diagnostic Test: pelvic X-ray examinations
|
Observational
|
|
- Hebei Medical University Third Hospital
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- The sensitivity of offshoring index (OFI)
- The specificity of OFI,MUI and TBOI
- The positive predictive value of OFI,MUI and TBOI
- (and 3 more...)
|
200 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03541122 |
HebeiMUth-003 |
|
February 1, 2018 |
October 2019 |
December 2019 |
May 30, 2018 |
May 30, 2018 |
|
- Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
|
|
| 81 |
NCT01159899 |
Unknown † |
Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee |
- Osteoarthritis
- Knee Osteoarthritis
- Osteochondritis Dissecans
- Osteonecrosis
|
- Procedure: Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis
|
Interventional
|
Early Phase 1 |
- Michel Assor, MD
- University of Marseille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- IKS, International Knee Score
- KOOS, Knee Injury and Osteoarthritis Outcome Score
|
50 |
All |
30 Years to 75 Years (Adult, Older Adult) |
NCT01159899 |
MSC- AS3 |
|
July 2010 |
December 2014 |
December 2014 |
July 12, 2010 |
January 8, 2013 |
|
- Knee and Lower Limb Institute, Dr Michel Assor
Marseille, France
|
|
| 82 |
NCT02018484 |
Completed |
Positioning of the Tibial Cut in Unicompartmental Medial Knee Replacement by Using Patient Specific Cutting Guides. |
|
- Procedure: Unicompartmental Knee Replacement
|
Interventional
|
Not Applicable |
- Rennes University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Success rate in performing the tibial cut
- Success rate in conserving a residual varus.
- Variations of other orientation parameters of the tibial cut and limb alignment at the different times of the procedure (per and post operative) .
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT02018484 |
2013-A01337-38 |
PSI-PUC |
December 2013 |
May 2016 |
May 2016 |
December 23, 2013 |
August 19, 2016 |
|
|
|
| 83 |
NCT03443102 |
Recruiting |
Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome |
- SARS Virus
- Long-Term Survivors
|
|
Observational
|
|
- Peking University People's Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- All-cause disability
- Cardiopulmonary function
- Life Life quaities mental distress
|
150 |
All |
Child, Adult, Older Adult |
NCT03443102 |
2018PHB010-01 |
|
January 25, 2018 |
July 1, 2018 |
December 1, 2018 |
February 22, 2018 |
February 26, 2018 |
|
- Peking University People's Hospital
Beijing, Beijing, China
|
|
| 84 |
NCT03016299 |
Unknown † |
The Histological Effect of Various Microfracture Techniques on Human Chondral & Sub-chondral Tissue - an Ex-Vivo Study |
- Partial or Total Hip Arthroplasty
- Ex-vivo Preparat of Femoral Head
|
- Procedure: microfracture techniques
|
Observational
|
|
|
Other |
- Observational Model: Cohort
|
|
40 |
All |
18 Years to 120 Years (Adult, Older Adult) |
NCT03016299 |
0167-16-MMC |
|
December 2016 |
June 2017 |
July 2017 |
January 10, 2017 |
January 10, 2017 |
|
|
|
| 85 |
NCT03012555 |
Completed |
Vitamin D3 in Patients With Sickle Cell Disease |
|
|
Observational
|
|
- Icahn School of Medicine at Mount Sinai
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 25(OH)D level
- Dexa Scan
- CRP level
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03012555 |
GCO 13-1056 |
|
October 2014 |
August 11, 2016 |
August 11, 2016 |
January 6, 2017 |
January 19, 2018 |
|
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 86 |
NCT03605940 |
Not yet recruiting |
A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease |
- Acute-graft-versus-host Disease
|
- Combination Product: Methoxsalen + ECP device
- Drug: Corticosteroids
|
Interventional
|
Phase 2 |
- Central Hospital, Nancy, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Probability of being free of treatment failure (probability of survival without relapse, additional line of treatment for aGVHD and systemic therapy for chronic GVHD)
- mean of the cumulative dose of steroids
- cumulative incidence rate of infections
- (and 14 more...)
|
78 |
All |
18 Years and older (Adult, Older Adult) |
NCT03605940 |
2017-005162-22
PSS2017/PCE-aGVHD-RUBIO/VS |
PCE-aGVHD |
October 1, 2018 |
April 1, 2021 |
April 1, 2022 |
July 30, 2018 |
July 30, 2018 |
|
|
|
| 87 |
NCT02984228 |
Recruiting |
Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis |
- Osteoarthritis
- Shoulder Pain
|
- Biological: PRP
- Drug: Hyaluronic Acid
- Device: Ultrasound
|
Interventional
|
Phase 4 |
- Hospital for Special Surgery, New York
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Shoulder Pain and Disability Index (SPADI) score
- Shoulder Function
- Pain medication usage
- (and 3 more...)
|
70 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT02984228 |
2015-188 |
|
December 2014 |
January 2019 |
August 2019 |
December 6, 2016 |
November 9, 2018 |
|
- Hospital for Special Surgery
New York, New York, United States
|
|
| 88 |
NCT01062503 |
Completed |
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC |
- Metastatic Prostate Cancer
- Bone Metastasis
|
|
Observational
|
|
- University Health Network, Toronto
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Patients given single dose of Zoledronic Acid 4mg IV
- Brief Pain Inventory Location Questionnaire
- FACT-BP Quality of Life Questionnaire
- We will monitor for uNTX, sCTX, BAP (fasting morning sample)
|
48 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01062503 |
REB 09-0688-C
PRIT9 |
SubDueP |
January 2010 |
June 2014 |
June 2014 |
February 4, 2010 |
April 27, 2015 |
|
- Princess Margaret Hospital
Toronto, Ontario, Canada
|
|
| 89 |
NCT02465684 |
Not yet recruiting |
Effect of Tourniquet on UKA |
|
- Procedure: unicondylar knee arthroplasty
|
Interventional
|
Not Applicable |
- Medical University Innsbruck
- Medical University Linz, Austria
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
30 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02465684 |
UKA-Tourniquet |
|
November 2016 |
January 2022 |
|
June 8, 2015 |
July 19, 2016 |
|
|
|
| 90 |
NCT02345915 |
Recruiting |
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia |
- Leukemia, Myeloid, Acute
- Acute Lymphoid Leukemia
|
- Other: Blood sample
- Other: Electrocardiogram
|
Interventional
|
Not Applicable |
- Institut Paoli-Calmettes
- Aix Marseille Université
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Late sequelae evaluation of young adult acute leukemia-survivors
- Quality-of-life assessment of young adult acute leukemia-survivors
- Comparison of the frequency of sequelae between children/adolescents (LEA cohort) and young adults acute leukemia survivors (LEA-JA)
|
90 |
All |
18 Years to 30 Years (Adult) |
NCT02345915 |
LEA-JA-IPC 2014-005 |
LEA-JA |
November 2014 |
May 2018 |
May 2019 |
January 26, 2015 |
September 5, 2017 |
|
- Institut Paoli-Calmettes
Marseille, France
|
|
| 91 |
NCT03785717 |
Completed
New |
Horizontal Ridge Augmentation in Mandible Usign ROG + ESWT |
|
- Procedure: ROG
- Procedure: ROG & ESWT
|
Interventional
|
Not Applicable |
- Universidad El Bosque, Bogotá
- Gloria Lafaurie
- Carlos Leal
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Bone width (in mm), as assessed using (CBCT) on a partially edentulous patients after ROG+ESWT.
|
28 |
All |
35 Years to 65 Years (Adult, Older Adult) |
NCT03785717 |
PCI2015-8351 |
|
August 2016 |
December 11, 2017 |
December 20, 2018 |
December 24, 2018 |
December 24, 2018 |
|
- Yamil Lesmes
Bogota, Colombia
|
|
| 92 |
NCT03709381 |
Recruiting |
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study |
- Adrenal Insufficiency
- Osteopenia, Osteoporosis
- Steroid Suppression of ACTH Secretion
|
- Drug: Low Dose Cosyntropin (ACTH) stimulation test
- Drug: High Dose Cosyntropin (ACTH) stimulation test
|
Interventional
|
Early Phase 1 |
- Nationwide Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Difference between VEGF levels at baseline and the peak VEGF level after low dose cosyntropin administration in healthy children and adolescents
- Difference between VEGF levels at baseline and the peak VEGF level after high dose cosyntropin administration in healthy children and adolescents
|
10 |
All |
9 Years to 17 Years (Child) |
NCT03709381 |
IRB17-00194 |
|
October 1, 2017 |
October 2018 |
June 2019 |
October 17, 2018 |
October 18, 2018 |
|
- Nationwide Children's Hospital
Columbus, Ohio, United States
|
|
| 93 |
NCT03040908 |
Not yet recruiting |
New Hemolysis Parameters in Sickle Cell Disease |
|
|
Observational
|
|
- Queen Fabiola Children's University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Correlation between new biological data and clinical phenotype
- Correlation between new biological data and 6-minute walk test
|
150 |
All |
6 Years to 25 Years (Child, Adult) |
NCT03040908 |
P2016/ONCO-HEMATO/HEMODREP |
HEMODREP |
October 1, 2018 |
April 1, 2020 |
April 30, 2020 |
February 2, 2017 |
July 4, 2018 |
|
|
|
| 94 |
NCT02425215 |
Recruiting |
HBOT Late Radiation Tissue Injury |
- Late Radiation Injury
- Chronic Pain
|
|
Observational
|
|
- University Health Network, Toronto
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Pain Intensity (11 point numeric rating scale, Brief Pain Inventory short form )
- Pain Disability (pain disability index)
- Quality of Life Measurement (EORTC QLQ C30)
- (and 3 more...)
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02425215 |
14-7413-BE |
|
June 2014 |
February 2019 |
April 2019 |
April 23, 2015 |
April 6, 2018 |
|
- University Health Network
Toronto, Ontario, Canada
|
|
| 95 |
NCT03639272 |
Completed |
Treatment of Talus Fractures: a Retrospective Study |
|
- Procedure: open reduction and internal fixation (ORIF).
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Evaluation of the quality reduction after surgery
- Evaluation of bone healing
- Evaluation of osteonecrosis
- (and 4 more...)
|
40 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03639272 |
4065/AO/17 |
TTF2017 |
January 1, 2007 |
December 31, 2012 |
February 28, 2018 |
August 21, 2018 |
August 21, 2018 |
|
|
|
| 96 |
NCT02480036 |
Recruiting |
Combining Intraoperative Radiotherapy With Kyphoplasty for Treatment of Spinal Metastases |
|
- Radiation: IORT with Kyphoplasty
- Device: Intrabeam®
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
10 |
All |
50 Years and older (Adult, Older Adult) |
NCT02480036 |
206824
206824091714 |
KYPHO-IORT |
December 2014 |
December 2018 |
December 2019 |
June 24, 2015 |
October 3, 2017 |
|
- Loyola University Medical Center
Maywood, Illinois, United States
|
|
| 97 |
NCT03096470 |
Completed |
Closed Reduction With Anesthesia and no Anesthesia for Developmental Dislocation of the Hip < 6 Months |
- Developmental Dislocation of the Hip
- Reduction Deformity of Limb
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Successful treatment
- Radiographic evaluation
|
30 |
All |
up to 6 Months (Child) |
NCT03096470 |
SChen1 |
|
March 1, 2017 |
March 1, 2017 |
March 1, 2017 |
March 30, 2017 |
March 30, 2017 |
|
|
|
| 98 |
NCT00001306 |
Completed |
Steroid Therapy in Autoimmune Premature Ovarian Failure |
- Autoimmune Disease
- Infertility
- Premature Ovarian Failure
|
|
Observational
|
|
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
33 |
Female |
18 Years to 39 Years (Adult) |
NCT00001306 |
920223
92-CH-0223 |
|
July 10, 1992 |
|
December 12, 2011 |
November 4, 1999 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 99 |
NCT00892242 |
Terminated |
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer |
|
|
Interventional
|
Phase 1 |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the safety and feasibility perioperative neoadjuvant zoledronic acid in patients with resectable pancreas cancer.
- Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.
- Determine the pharmacodynamics on selected immune cell subgroups in the peripheral blood and marrow by flow cytometric analysis.
- (and 8 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT00892242 |
09-0589 / 201109094 |
|
December 2009 |
April 2013 |
April 2013 |
May 4, 2009 |
September 22, 2014 |
|
- Washington University School of Medicine
St. Louis, Missouri, United States
|
|
| 100 |
NCT03291015 |
Not yet recruiting |
Kienbock Disease Radiographic Guided Treatment Versus Arthroscopic Guided Treatment |
|
- Device: radiographic
- Device: arthroscopy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison Between Radiological Guided Treatment(15Patient) And Arthroscopic Guided Treatment(Other 15Patient) Of KIENBOCK Disease
|
30 |
All |
20 Years to 60 Years (Adult) |
NCT03291015 |
kienbock disease |
|
October 1, 2017 |
December 1, 2018 |
February 1, 2019 |
September 25, 2017 |
September 25, 2017 |
|
|
|
Create an RSS feed from your search for:
Download the search results for: